- Generic name
- Levetiracetam
- Strength
- 100 mg/ml
- Dosage form
- Suspension
- Manufactured by
- Square Pharmaceuticals PLC.
Iracet Suspension
About Iracet 100 mg/ml Suspension
Iracet is a brand of levetiracetam, an adjunct anti-epileptic medicine available as a 100 mg/ml suspension. It is used alongside other treatments for certain types of seizures, with the doctor deciding how it is used.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Iracet 100 mg/ml Suspension?
Iracet suspension contains levetiracetam, a medicine from the adjunct anti-epileptic group. It is made by Square Pharmaceuticals PLC in a liquid form with a strength of 100 mg/ml. Doctors prescribe levetiracetam for certain seizure types in adults, adolescents, children and infants from one month of age, and sometimes as the only treatment in newly diagnosed partial-onset seizures in adults and adolescents from sixteen years. Iracet is given as part of a treatment plan set by the doctor. The dose and course depend on the person's age, weight and response, and are decided by the doctor.
Uses of Iracet
Levetiracetam is used for partial-onset seizures, with or without secondary generalisation. It can be given alongside other anti-epileptic medicines in adults, adolescents, children and infants from one month of age. It is also used alone in adults and adolescents from sixteen years with newly diagnosed epilepsy. Whether Iracet suits a particular person is a decision for the doctor.
How to use Iracet
Iracet suspension is a liquid taken by mouth. The doctor sets the dose and how often it is given, based on the person's age, weight and response to treatment. Do not change the amount or stop the medicine unless the doctor says so, because stopping suddenly can be harmful. If a dose is missed, ask the doctor or pharmacist what to do. Follow the doctor's instructions and keep regular appointments.
Side effects of Iracet
In adults, common side effects include sleepiness, weakness, infection and dizziness. In children, tiredness, aggression, nasal congestion, decreased appetite and irritability are reported. Other side effects can occur. Anyone who notices unusual symptoms or feels unwell while taking Iracet should tell the doctor. The doctor or pharmacist can explain what to watch for and what to do.
Safety and precautions
Levetiracetam is not recommended during pregnancy, or in women who could become pregnant and are not using contraception, unless the doctor considers it necessary. It passes into breast milk, so breastfeeding is not recommended; if treatment is needed while breastfeeding, the doctor weighs the benefits and risks. People with kidney problems, or with severely impaired liver function, may need dose adjustment, so the doctor should be told about these conditions. Rarely, levetiracetam has been linked to acute kidney injury and to decreases in blood cell counts. Tell the doctor about all medicines being taken and about any allergies.
Frequently asked questions
What does the generic name levetiracetam mean?
Levetiracetam is the generic name of the active substance in Iracet. It belongs to a group of medicines called adjunct anti-epileptic drugs. The brand name Iracet is the product name given by the manufacturer, Square Pharmaceuticals PLC.
What is Iracet used for and what kind of medicine is it?
Iracet contains levetiracetam, an adjunct anti-epileptic medicine. It is used for partial-onset seizures, either alongside other anti-epileptic medicines or, in some newly diagnosed adults and adolescents, alone. The doctor decides whether it is suitable and how it fits into the treatment plan.
What do the dosage form and strength mean?
Iracet comes as a suspension, which is a liquid medicine taken by mouth. The strength is 100 mg/ml, meaning each millilitre of the liquid contains 100 mg of levetiracetam. The doctor decides how much to give and for how long; the amount is not fixed by the strength alone.
Can I stop taking Iracet on my own?
No. Stopping an anti-epileptic medicine suddenly can be harmful. The doctor decides when and how to change or stop treatment. If you have concerns, or if side effects bother you, speak to the doctor or pharmacist before making any change.
Also available as
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.